Glenmark Pharmaceuticals has received first-to-file status for three of its abbreviated new drug applications (ANDA) that have combined revenues of over $2 billion (about Rs 9,600 crore at current exchange rates) in the
First-to-file status typically recognises a generic company as being the first to file a para IV application challenging a particular patent and seeking to manufacture generic versions of a drug which, at present, does not have generic competition.
With the first-to-file status comes a 180-day marketing exclusivity (from the date of approval of the ANDA), during which the Food and Drug Adminstration may not approve another ANDA for such generic product. During this period, the first-to-file generic company can reap huge benefits on the sale of the generic drug, which is typically sold at a price ranging from 70-80% of the brand product price. This would be before other generic equivalents enter the market following the expiration of the 180-day exclusivity period.
The latest first-to-file status was granted for Ezetimibe in April this year. Litigation for all three filings is in various stages, but if Glenmark wins, it will get a 180-day exclusive marketing period. Six month marketing exclusivity periods are much sought after, as it gives a company an edge over the competition in gaining market share before the space becomes highly competitive.
crackcrack| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: